Woman researcher looking at test tube samples.

Clinical Research

Today’s Commitment. Tomorrow’s Cure.

The Clinical Research Program at Prism Health North Texas was created after the Peabody Health Center was awarded a seven-year grant to be a network clinical research site (CRS) of the National Institutes of Health’s (NIH) AIDS Clinical Trials Group (ACTG) in 2006. In 2007, the organization began to partner with pharmaceutical companies to participate in industry-sponsored clinical trials. The Clinical Research Program has focused on research studies for HIV treatment, HIV Prevention, Hepatitis C Treatment, TB Prevention, and HIV co-morbidities such as HIV and Aging, HIV-associated neurocognitive disorders, and cardiovascular disease in patients living with HIV.

Be a Study Participant

Prism Health North Texas is committed to the development of new medications and devices to serve our community better and participates in several new trials every year. If you are interested in participating in a clinical trial, review the Current Enrolling Studies list below and complete the interest form. The clinical research department also has study coordinators who can help determine your eligibility for the studies. If you have questions or need help navigating your eligibility, contact a study coordinator at [email protected].

Research Participant Interest Form
Female Provider Drawing Blood from Male Patient

Types of Clinical Research Studies

Newly Diagnosed Trials

Studies for patients who were recently diagnosed with HIV. These studies are for patients who have never tried HIV medications before or have been without medication for over three months.

View Enrolling Trials

Medication Switch Trials

Studies for patients who have been stable on an HIV medication and are willing to try a new experimental treatment.

View Enrolling Trials

Observational Trials

Observational clinical trials can be for patients who are not living with HIV. These studies are for observing risk factors, questionnaires, or diagnostic tests.

View Enrolling Trials

Featured Study: Study for healthy participants who are low-risk of HIV-1 infection

The MK8527-007 study will help researchers learn more about the safety of different doses of an investigational study medicine, how the study medicine works in the body, and about any side effects. Researchers want to study this in healthy adults who are at low risk of getting a human immunodeficiency virus (HIV) infection. If you are interested in learning more or participating in the trial, complete the Study Interest Form.

Study Information and Eligibility:

  • Age: 18-65
  • Gender: Any
  • Length: 2 Years
  • Characteristics: For patients who are HIV negative with a low risk of getting an HIV infection, do not use or inject un-prescribed drugs, and do not have a history of drug or alcohol abuse or dependence.
Complete the Research Participant Interest Form
Black female provider with tablet talking to Asian female patient

Current Enrolling Clinical Research Studies

Newly Diagnosed Trials

 

  • GS-US-544-5905 – 60-Day Clinical Research Study for Novel HIV Medication
    • Patients will dose, once or multiple times, frontline HIV treatment. Visits are required every day for 11 days, then three follow-up appointments.
  • MK8591A-053 – Comparing Brand New Medication to Biktarvy (Currently paused until Spring 2024)
    • Two-year and two-month study where the patient will take two medications daily: an antiretroviral (ARV) treatment and a placebo.

Medication Switch Trials

 

  • GS-US-6216289 – Comparing Bictegravir/Lenacapavir versus current therapy in people with HIV-1
    • People with HIV-1 who are successfully treated with a complicated regimen.
  • MK8591A-052 – Comparing Brand New Medication to Biktarvy (Currently paused until Spring 2024)
    • Two-year and two-month study where the patient will take two medications daily: an antiretroviral (ARV) treatment and a placebo.
    • The study is for treatment-experienced patients.

Observational Trials

 

  • PROMISE – Living with HIV: Real-World Setting Questionnaires
    • Questionnaire study for patients on an HIV treatment who are resistant to three or more HIV drug classes or patients taking Trogarzo.
  • PREFERA – Understanding the perspectives and challenges with historical oral therapy use
    • For patients currently receiving CABENUVA.

Other Studies

 

  • AbbVie-M19-965 – Study evaluating intravenous budigalimab and/or ABBV-382 in people living with HIV
    • For people living with HIV on stable ART undergoing analytical treatment interruption.
  • ACTG-5418-Tpoxx – Study of Tecovirimat for Human Monkeypox Virus
    • For diagnosed TPOXX Patients.
  • MK8527-007 – Study for healthy participants who are low-risk of HIV-1 infection
    • Patients will receive a once-a-month capsule of MK-8527 to evaluate the safety and tolerability of the drug.

Interested in being a participant in one of the current enrolling studies?

See past studies PHNTX has participated in

Research Publications

  • Comparable Viral Decay with Initial Dolutegravir Plus Lamivudine Versus Dolutegravir-Based Triple Therapy // Read More →
  • Hepatic Steatosis in People Living with HIV: Effect of Sex and Race/Ethnicity // Read More →

Frequently Asked Questions

About Clinical Research

Participating in a Study Trial and Appointments

Study Medication and Results

Other FAQs

Community Advisory Board

The Research Program has an active Community Advisory Board (CAB) dedicated to community outreach and peer education. The CAB is made up of five men and two women who are passionate about HIV research, treatment, and prevention. The CAB meets every other month and reviews studies in the early phase of development to provide community feedback on the study’s design, which helps the sponsor improve study objectives, potential recruitment, and participant retention. The CAB also provides input on ways to recruit participants and keep them engaged while participating in a study.